As of 2026-04-02, the Intrinsic Value of Jagson Pal Pharmaceuticals Ltd (JAGSNPHARM.NS) is 93.07 INR. This JAGSNPHARM.NS valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 185.66 INR, the upside of Jagson Pal Pharmaceuticals Ltd is -49.90%.
The range of the Intrinsic Value is 77.56 - 117.93 INR
Based on its market price of 185.66 INR and our intrinsic valuation, Jagson Pal Pharmaceuticals Ltd (JAGSNPHARM.NS) is overvalued by 49.90%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | 77.56 - 117.93 | 93.07 | -49.9% |
| DCF (Growth 10y) | 98.82 - 147.77 | 117.84 | -36.5% |
| DCF (EBITDA 5y) | 114.92 - 148.17 | 122.32 | -34.1% |
| DCF (EBITDA 10y) | 125.91 - 173.26 | 140.69 | -24.2% |
| Fair Value | 152.71 - 152.71 | 152.71 | -17.75% |
| P/E | 103.11 - 187.80 | 146.04 | -21.3% |
| EV/EBITDA | 91.99 - 154.08 | 110.40 | -40.5% |
| EPV | 25.08 - 31.52 | 28.30 | -84.8% |
| DDM - Stable | 27.72 - 57.39 | 42.56 | -77.1% |
| DDM - Multi | 67.50 - 105.60 | 82.13 | -55.8% |
| Market Cap (mil) | 12,431.79 |
| Beta | 0.40 |
| Outstanding shares (mil) | 66.96 |
| Enterprise Value (mil) | 12,392.22 |
| Market risk premium | 8.31% |
| Cost of Equity | 16.50% |
| Cost of Debt | 7.46% |
| WACC | 16.42% |